Daiwa Securities Group Inc. Cuts Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Daiwa Securities Group Inc. cut its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 7.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,942 shares of the medical instruments supplier’s stock after selling 1,430 shares during the quarter. Daiwa Securities Group Inc. owned 0.07% of ICU Medical worth $3,269,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of ICU Medical by 21.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after acquiring an additional 55,588 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in ICU Medical by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after acquiring an additional 27,927 shares during the period. WCM Investment Management LLC grew its position in ICU Medical by 1.3% during the 3rd quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock worth $45,272,000 after acquiring an additional 3,407 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in ICU Medical by 11.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock worth $25,710,000 after purchasing an additional 22,310 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, KeyCorp boosted their price target on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Trading Up 1.3 %

NASDAQ:ICUI opened at $159.75 on Thursday. The company has a 50-day moving average price of $175.61 and a 200-day moving average price of $146.51. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of -34.62 and a beta of 0.66. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12 month low of $83.26 and a 12 month high of $196.26.

Insider Buying and Selling

In related news, COO Christian B. Voigtlander sold 1,430 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total transaction of $225,940.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David C. Greenberg sold 972 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the transaction, the director now owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. This trade represents a 16.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,866 shares of company stock valued at $7,284,854 over the last three months. Corporate insiders own 6.70% of the company’s stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.